Vaborem

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
26-07-2023
产品特点 产品特点 (SPC)
26-07-2023
公众评估报告 公众评估报告 (PAR)
18-12-2018

有效成分:

meropenem trihydrate, vaborbactam

可用日期:

Menarini International Operations Luxembourg S.A.

ATC代码:

J01DH

INN(国际名称):

meropenem, vaborbactam

治疗组:

Antibacterials for systemic use,

治疗领域:

Urinary Tract Infections; Bacteremia; Bacterial Infections; Respiratory Tract Infections; Pneumonia; Pneumonia, Ventilator-Associated

疗效迹象:

Vaborem is indicated for the treatment of the following infections in adults:Complicated urinary tract infection (cUTI), including pyelonephritisComplicated intra-abdominal infection (cIAI)Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Vaborem is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents.

產品總結:

Revision: 7

授权状态:

Authorised

授权日期:

2018-11-20

资料单张

                                25
B. PACKAGE LEAFLET
26
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
VABOREM 1 G/1 G POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
meropenem/vaborbactam
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Vaborem is and what it is used for
2.
What you need to know before you are given Vaborem
3.
How you will be given Vaborem
4.
Possible side effects
5.
How to store Vaborem
6.
Contents of the pack and other information
1.
WHAT VABOREM IS AND WHAT IT IS USED FOR
WHAT VABOREM IS
Vaborem is an antibiotic medicine that contains two active substances:
meropenem and vaborbactam.
•
Meropenem belongs to group of antibiotics called “carbapenems”. It
can kill many types of bacteria
by preventing them from building the protective walls that surround
their cells.
•
Vaborbactam is a “beta lactamase inhibitor”. It blocks the action
of an enzyme that allows some
bacteria to resist the action of meropenem. This helps meropenem kill
some bacteria that it cannot
kill on its own.
WHAT VABOREM IS USED FOR
Vaborem is used in adults to treat certain serious bacterial
infections:
•
of the bladder or kidneys (urinary tract infections)
•
of the stomach and gut (intra-abdominal infections)
•
of the lungs (pneumonia)
It is also used to treat infections
•
of the blood associated with any of the infections mentioned above
•
caused by bacteria that other antibiotics may not be able to kill
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN VABOREM
YOU MUST NOT BE GIVEN VABOREM
IF
•
you are allergic to meropenem, vaborbactam or the other ingredients of
this medicine (listed in
section 6).
•
you are allergic to other carbapenem antibiotics (the group to which
merope
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Vaborem 1 g/1 g powder for concentrate for solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains meropenem trihydrate equivalent to 1 g meropenem,
and 1 g vaborbactam.
After reconstitution, 1 ml of the solution contains 50 mg meropenem
and 50 mg vaborbactam (see section
6.6).
Excipient with known effect:
Each vial contains 10.9 mmol of sodium (approximately 250 mg).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for concentrate for solution for infusion (powder for
concentrate).
White to light yellow powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Vaborem is indicated for the treatment of the following infections in
adults (see sections 4.4 and 5.1):
•
Complicated urinary tract infection (cUTI), including pyelonephritis
•
Complicated intra-abdominal infection (cIAI)
•
Hospital-acquired pneumonia (HAP), including ventilator associated
pneumonia (VAP).
Treatment of patients with bacteraemia that occurs in association
with, or is suspected to be associated
with, any of the infections listed above.
Vaborem is also indicated for the treatment of infections due to
aerobic Gram-negative organisms in
adults with limited treatment options (see sections 4.2, 4.4 and 5.1).
Consideration should be given to official guidance on the appropriate
use of antibacterial agents.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Vaborem should be used to treat infections due to aerobic
Gram-negative organisms in adult patients with
limited treatment options only after consultation with a physician
with appropriate experience in the
management of infectious diseases (see sections 4.4 and 5.1).
Posology
3
Table 1 shows the recommended intravenous dose for patients with a
creatinine clearance
(CrCl) ≥40 ml/min (see sections 4.4 and 5.1).
TABLE 1:
RECOMMENDED INTRAVENOUS DOSE FOR PATIENTS WITH A CREATININE CLEARANCE
(CRCL) ≥40 ML/MIN
1
Type of infection
Dose of Vaborem
(meropenem/
v
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 26-07-2023
产品特点 产品特点 保加利亚文 26-07-2023
公众评估报告 公众评估报告 保加利亚文 18-12-2018
资料单张 资料单张 西班牙文 26-07-2023
产品特点 产品特点 西班牙文 26-07-2023
公众评估报告 公众评估报告 西班牙文 18-12-2018
资料单张 资料单张 捷克文 26-07-2023
产品特点 产品特点 捷克文 26-07-2023
公众评估报告 公众评估报告 捷克文 18-12-2018
资料单张 资料单张 丹麦文 26-07-2023
产品特点 产品特点 丹麦文 26-07-2023
公众评估报告 公众评估报告 丹麦文 18-12-2018
资料单张 资料单张 德文 26-07-2023
产品特点 产品特点 德文 26-07-2023
公众评估报告 公众评估报告 德文 18-12-2018
资料单张 资料单张 爱沙尼亚文 26-07-2023
产品特点 产品特点 爱沙尼亚文 26-07-2023
公众评估报告 公众评估报告 爱沙尼亚文 18-12-2018
资料单张 资料单张 希腊文 26-07-2023
产品特点 产品特点 希腊文 26-07-2023
公众评估报告 公众评估报告 希腊文 18-12-2018
资料单张 资料单张 法文 26-07-2023
产品特点 产品特点 法文 26-07-2023
公众评估报告 公众评估报告 法文 18-12-2018
资料单张 资料单张 意大利文 26-07-2023
产品特点 产品特点 意大利文 26-07-2023
公众评估报告 公众评估报告 意大利文 18-12-2018
资料单张 资料单张 拉脱维亚文 26-07-2023
产品特点 产品特点 拉脱维亚文 26-07-2023
公众评估报告 公众评估报告 拉脱维亚文 18-12-2018
资料单张 资料单张 立陶宛文 26-07-2023
产品特点 产品特点 立陶宛文 26-07-2023
资料单张 资料单张 匈牙利文 26-07-2023
产品特点 产品特点 匈牙利文 26-07-2023
公众评估报告 公众评估报告 匈牙利文 18-12-2018
资料单张 资料单张 马耳他文 26-07-2023
产品特点 产品特点 马耳他文 26-07-2023
公众评估报告 公众评估报告 马耳他文 18-12-2018
资料单张 资料单张 荷兰文 26-07-2023
产品特点 产品特点 荷兰文 26-07-2023
公众评估报告 公众评估报告 荷兰文 18-12-2018
资料单张 资料单张 波兰文 26-07-2023
产品特点 产品特点 波兰文 26-07-2023
公众评估报告 公众评估报告 波兰文 18-12-2018
资料单张 资料单张 葡萄牙文 26-07-2023
产品特点 产品特点 葡萄牙文 26-07-2023
公众评估报告 公众评估报告 葡萄牙文 18-12-2018
资料单张 资料单张 罗马尼亚文 26-07-2023
产品特点 产品特点 罗马尼亚文 26-07-2023
公众评估报告 公众评估报告 罗马尼亚文 18-12-2018
资料单张 资料单张 斯洛伐克文 26-07-2023
产品特点 产品特点 斯洛伐克文 26-07-2023
公众评估报告 公众评估报告 斯洛伐克文 18-12-2018
资料单张 资料单张 斯洛文尼亚文 26-07-2023
产品特点 产品特点 斯洛文尼亚文 26-07-2023
公众评估报告 公众评估报告 斯洛文尼亚文 18-12-2018
资料单张 资料单张 芬兰文 26-07-2023
产品特点 产品特点 芬兰文 26-07-2023
公众评估报告 公众评估报告 芬兰文 18-12-2018
资料单张 资料单张 瑞典文 26-07-2023
产品特点 产品特点 瑞典文 26-07-2023
公众评估报告 公众评估报告 瑞典文 18-12-2018
资料单张 资料单张 挪威文 26-07-2023
产品特点 产品特点 挪威文 26-07-2023
资料单张 资料单张 冰岛文 26-07-2023
产品特点 产品特点 冰岛文 26-07-2023
资料单张 资料单张 克罗地亚文 26-07-2023
产品特点 产品特点 克罗地亚文 26-07-2023
公众评估报告 公众评估报告 克罗地亚文 18-12-2018

查看文件历史